ISA 2022 | Elotuzumab and IMiDs in patients with R/R AL amyloidosis with advanced organ involvement
Tobias Dittrich, MD, Heidelberg University, Heidelberg, Germany, shares the results of a retrospective study evaluating the safety and efficacy of elotuzumab in combination with IMiDs in patients with AL amyloidosis with advanced organ involvement and refractory to proteasome inhibitors and daratumumab. The study showed that 30% of patients were able to achieve hematologic response and did not report safety signals, thereby suggesting elotuzumab as a potential option in this patient population.
This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
